AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00739583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodophor 0.7% and IPA 74% w/w
Description: Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
Study NCT03567083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
Study NCT02079207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP606
Description: 13-valent peumococcal conjugate vaccine(13vPnC)
Study NCT02079207 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prodiax-23
Description: 23-valent peumococcal polysaccharide vaccine(23vPS)
Study NCT02372175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
Study NCT00401466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: ICD with Biotronik Home Monitoring capability
Study NCT00401466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator
Description: ICD with Biotronik Home Monitoring capability
Study NCT03135132 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Recommend to consume usual diet during 12-week study period
Study NCT03135132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCD group
Description: Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
Study NCT01084928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Classes
Description: The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
Study NCT00506285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System (MTS)
Description: MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
Study NCT00506285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: This patch is designed to appear identical to the actual intervention patch
Study NCT05054829 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEERS®: program for the education and enrichment of relational skills
Description: providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)
Study NCT05054829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS®: program for the education and enrichment of relational skills
Description: providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)
Study NCT02687503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic
Description: All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
Study NCT03976310 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 48 weeks of Benralizumab
Description: Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
Study NCT03976310 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Computed tomography
Description: Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
Study NCT01426620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
Study NCT01781611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release dipyridamole 200mg/aspirin 25mg
Description: one tablet twice daily for 24 weeks
Study NCT01781611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 81mg aspirin
Description: half a tablet twice daily for 24 weeks
Study NCT00951860 — intervention group
Intervention type: OTHER
Intervention: Autonomic Nervous System activity
Description: Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
Study NCT04572490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: periapical radiograph
Description: alveolar bone loss measurement on standardized parallel periapical radiograph
Study NCT02364453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACAP38
Description: Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
Study NCT03345862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-pharmacological multicomponent
Description: Following the proposal of Nicholson \& Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home \[30-60 minutes\] for 16 weeks (1 fortnightly session) and 5 telephone sessions \[20 min.\] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
Study NCT00179010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
Study NCT00179010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Mono Phosphate (AMP)
Description: Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
Study NCT01942655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample and recto-colic biopsies
Study NCT01327937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apligraf
Description: Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
Study NCT01327937 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Dressing Group
Description: Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
Study NCT00432861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PANCRECARB® (pancrelipase)
Description: Capsules
Study NCT00432861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT04127305 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT03019458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MINGO
Description: 6 20oz sachets will be taken daily by intervention group
Study NCT06283602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: oral health status
Description: the dentists examined the dried teeth with a probe and mount mirror in a dental unit.
Study NCT02278796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM
Description: Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
Study NCT02278796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAM
Description: Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
Study NCT00021398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00021398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00021398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00021398 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00997243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lintuzumab
Description: Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
Study NCT00997243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: 75mg/m2 IV/SC daily on days 1-7.
Study NCT02521259 — intervention group
Intervention type: DEVICE
Intervention: BIS
Description: BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
Study NCT03330119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alternate Management
Description: With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
Study NCT03330119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
Study NCT03774992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Description: Custom fit, form stable contact lenses
Study NCT03841344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Evaluation of the utility of candidate endpoints in PAH trials
Study NCT02460471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: palliative radiation therapy
Description: thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
Study NCT02949518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Pathway (ERP) for Spine
Description: The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
Study NCT04073823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexitouch Plus
Description: Flexitouch Plus full arm and core treatment
Study NCT04073823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus FT with software modification
Description: Flexitouch Plus full arm and trunk/chest treatment
Study NCT04390815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Adding insulin to conventional wound treatment
Study NCT04390815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Adding insulin to conventional wound treatment
Study NCT03391167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
Study NCT03391167 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT03391167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT06309303 — intervention group
Intervention type: OTHER
Intervention: Clinical evaluation
Description: Evaluation of clinical manifestation, laboratory ad imaging testing results, disease course, treatment and outcome
Study NCT00123513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
Study NCT00123513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Increase routing physical activity, walking routes, stairs intervention, etc.
Study NCT00123513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment
Description: Cafeteria and vending machine changes and identification of opportunities of physical activity.
Study NCT01567163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
Study NCT01567163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 75 milligrams/square meter (mg/m\^2) intravenous infusion administered on Day 1 of each 3-week cycle
Study NCT03142217 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study of dysarthria in patients with Huntington's disease
Description: Study of dysarthria in patients with Huntington's disease
Study NCT04499040 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: Blood samples to assess biological parameters such as:
Study NCT04499040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples to assess biological parameters such as:
Study NCT04499040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal samples
Description: Microbiota analysis
Study NCT04499040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal samples
Description: Microbiota analysis
Study NCT04499040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological
Description: Neuropsychological assessment
Study NCT04266743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetMe Monitor
Description: For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI10773 high dose
Description: placebo tablets once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose tablet once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 open label
Description: Patients receive BI 10773 high dose tablets open label once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI10773 low dose
Description: placebo tablets once daily
Study NCT03648931 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group Discussion (FGD)
Description: No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding